Pfizer Inc. $PFE Stake Cut by Simplicity Wealth LLC

Key Points

• Simplicity Wealth LLC reduced its stake in Pfizer Inc. (NYSE:PFE) by 19.2%, holding 59,988 shares after selling 14,255 shares in the second quarter, worth approximately $1.454 million.
• Pfizer's stock is currently down 3.4% and has a market capitalization of $150.38 billion, with a 52-week low of $20.92 and a high of $30.43.
• In its latest earnings report, Pfizer reported an EPS of $0.78, beating estimates and achieving a revenue of $14.65 billion, up 10.3% year-over-year.

Simplicity Wealth LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 19.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 59,988 shares of the biopharmaceutical company's stock after selling 14,255 shares during the period. Simplicity Wealth LLC's holdings in Pfizer were worth $1,454,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. GKV Capital Management Co. Inc. acquired a new stake in Pfizer during the first quarter worth about $27,000. North Capital Inc. bought a new position in shares of Pfizer during the first quarter valued at approximately $28,000. Bayforest Capital Ltd acquired a new stake in shares of Pfizer during the 1st quarter worth approximately $28,000. Horizon Financial Services LLC bought a new stake in shares of Pfizer in the 1st quarter worth approximately $35,000. Finally, WPG Advisers LLC acquired a new position in Pfizer during the 1st quarter valued at approximately $35,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Down 3.4%

PFE stock opened at $26.45 on Tuesday. The firm's 50-day moving average is $24.72 and its two-hundred day moving average is $24.12. The company has a market capitalization of $150.38 billion, a price-to-earnings ratio of 14.07, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the business earned $0.60 earnings per share. The business's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on PFE shares. Wall Street Zen lowered Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday, September 28th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a report on Saturday, September 27th. Morgan Stanley boosted their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. UBS Group restated a "neutral" rating and issued a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Citigroup lifted their price target on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $28.41.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.